Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 Study of CoVLP COVID-19 Vaccine
NCT04636697Phase 3Active, not recruiting
- Sponsor
- Medicago Inc.
- Start
- Nov 2020
- Primary completion
- Aug 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 6
01
Overview
A Phase 3 trial of Covifenz in coronavirus disease 2019 (COVID-19), sponsored by Medicago Inc.. Started Nov 2020; status: active, not recruiting.
02
Drugs
Covifenz
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04636697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04636697.